Exploring therapeutic avenues: mesenchymal stem/stromal cells and exosomes in confronting enigmatic biofilm-producing fungi
Özet
Fungal infections concomitant with bioflms can demonstrate an elevated capacity to withstand substantially higher concentrations of antifungal agents, contrasted with infectious diseases caused by planktonic cells. This inherent resilience
intrinsic to bioflm-associated infections engenders a formidable impediment to efective therapeutic interventions. The
diferent mechanisms that are associated with the intrinsic resistance of Candida species encompass drug sequestration by
the matrix, drug efux pumps, stress response cell density, and the presence of persister cells. These persisters, a subset of
fungi capable of surviving hostile conditions, pose a remarkable challenge in clinical settings in virtue of their resistance to
conventional antifungal therapies. Hence, an exigent imperative has arisen for the development of novel antifungal therapeutics with specifc targeting capabilities focused on these pathogenic persisters. On a global scale, fungal persistence and their
resistance within bioflms generate an urgent clinical need for investigating recently introduced therapeutic strategies. This
review delves into the unique characteristics of Mesenchymal stem/stromal cells (MSCs) and their secreted exosomes, which
notably exhibit immunomodulatory and regenerative properties. By comprehensively assessing the current literature and
ongoing research in this feld, this review sheds light on the plausible mechanisms by which MSCs and their exosomes can
be harnessed to selectively target fungal persisters. Additionally, prospective approaches in the use of cell-based therapeutic
modalities are examined, emphasizing the importance of further research to overcome the enigmatic fungal persistence.